Ninety percent of patients who die from cancer, die from stage IV, metastatic disease, when the malignant cells spread throughout the body where they interfere with organ function leading to organ failure and death.

 

We discovered a unique phenotype adapted by the metastatic cancer cells during dissemination and are developing antibody-based therapeutics against a set of novel and unique molecular targets discovered using our proprietary Reconstructed Metastasis (rMet™) platform.